% alzhub.org library filter
% Source: https://alzhub.org/research?author=Brunstein+F&access=free
% 3 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{teng2022-35696185,
  author  = {Teng, E. and Manser, P. T. and Pickthorn, K. and Brunstein, F. and Blendstrup, M. and Sanabria Bohorquez, S. and Wildsmith, K. R. and Toth, B. and others},
  title   = {{Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial}},
  journal = {JAMA neurology},
  year    = {2022},
  doi     = {10.1001/jamaneurol.2022.1375},
  pmid    = {35696185},
  url     = {https://doi.org/10.1001/jamaneurol.2022.1375}
}

@article{monteiro2023-37643887,
  author  = {Monteiro, C. and Toth, B. and Brunstein, F. and Bobbala, A. and Datta, S. and Ceniceros, R. and Sanabria Bohorquez, S. M. and Anania, V. G. and others},
  title   = {{Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet}},
  journal = {Neurology},
  year    = {2023},
  doi     = {10.1212/wnl.0000000000207663},
  pmid    = {37643887},
  url     = {https://doi.org/10.1212/wnl.0000000000207663}
}

@article{salloway2018-30231896,
  author  = {Salloway, S. and Honigberg, L. A. and Cho, W. and Ward, M. and Friesenhahn, M. and Brunstein, F. and Quartino, A. and Clayton, D. and others},
  title   = {{Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE)}},
  journal = {Alzheimer's research \& therapy},
  year    = {2018},
  doi     = {10.1186/s13195-018-0424-5},
  pmid    = {30231896},
  url     = {https://doi.org/10.1186/s13195-018-0424-5}
}